2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management
S Susanibar‐Adaniya, SK Barta - American journal of …, 2021 - Wiley Online Library
Diffuse large B cell lymphoma (DLBCL), the most common type of Non‐Hodgkin lymphoma
(NHL), comprises a heterogeneous group of diseases with different biology, clinical …
(NHL), comprises a heterogeneous group of diseases with different biology, clinical …
Immunotherapy of neuroblastoma: facts and hopes
While the adoption of multimodal therapy including surgery, radiation, and aggressive
combination chemotherapy has improved outcomes for many children with high-risk …
combination chemotherapy has improved outcomes for many children with high-risk …
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
G Ghilardi, JA Fraietta, JN Gerson, VM Van Deerlin… - Nature Medicine, 2024 - nature.com
We report a T cell lymphoma (TCL) occurring 3 months after anti-CD19 chimeric antigen
receptor (CAR) T cell immunotherapy for non-Hodgkin B cell lymphoma. The TCL was …
receptor (CAR) T cell immunotherapy for non-Hodgkin B cell lymphoma. The TCL was …
Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance …
PURPOSE Alliance/CALGB 50303 (NCT00118209), an intergroup, phase III study,
compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide …
compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide …
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
C Melani, R Lakhotia, S Pittaluga… - … England Journal of …, 2024 - Mass Medical Soc
Background The identification of oncogenic mutations in diffuse large B-cell lymphoma
(DLBCL) has led to the development of drugs that target essential survival pathways, but …
(DLBCL) has led to the development of drugs that target essential survival pathways, but …
Vincristine in combination therapy of cancer: emerging trends in clinics
J Škubník, VS Pavlíčková, T Ruml, S Rimpelová - Biology, 2021 - mdpi.com
Simple Summary Vincristine is a vinca alkaloid naturally occurring in Catharanthus roseus. It
belongs to antimitotic compounds, which arrest the cell cycle via disrupting microtubule …
belongs to antimitotic compounds, which arrest the cell cycle via disrupting microtubule …
[HTML][HTML] Apoptosis, necroptosis, and pyroptosis as alternative cell death pathways induced by chemotherapeutic agents?
For decades, common chemotherapeutic drugs have been established to trigger apoptosis,
the preferred immunologically “silent” form of cell death. The primary objective of this review …
the preferred immunologically “silent” form of cell death. The primary objective of this review …
[HTML][HTML] Diffuse large B-cell lymphoma (DLBCL): early patient management and emerging treatment options
P Vodicka, P Klener, M Trneny - OncoTargets and Therapy, 2022 - ncbi.nlm.nih.gov
Diffuse large B-cell lymphoma (DLBCL) represents a curable disease with a 60–70%
chance of cure with current R-CHOP chemoimmunotherapy. However, 30–40% of patients …
chance of cure with current R-CHOP chemoimmunotherapy. However, 30–40% of patients …
Challenges and opportunities in the management of diffuse large B‐cell lymphoma in older patients
M Di, SF Huntington, AJ Olszewski - The Oncologist, 2021 - academic.oup.com
Most patients with diffuse large B‐cell lymphoma (DLBCL) are diagnosed at age 60 years or
older. Challenges to effective therapy among older individuals include unfavorable biologic …
older. Challenges to effective therapy among older individuals include unfavorable biologic …
Defining and treating high-grade B-cell lymphoma, NOS
High-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), is a recently introduced
diagnostic category for aggressive B-cell lymphomas. It includes tumors with Burkitt-like or …
diagnostic category for aggressive B-cell lymphomas. It includes tumors with Burkitt-like or …